Analysis and variable Hazard ratio (95% confidence interval) P value
Primary analysis
Composite (univariate)
1.002 (0.999–1.005)
.24
Composite outcome (multivariable)
1.002 (0.999–1.005)
.16
Age (per 5-year increase)
0.995 (0.992–0.998)
<.001
Sex (male)
1.002 (0.999–1.005)
.15
Asthma/chronic lung disease
1.059 (1.056–1.063)
<.001
Metabolic/endocrine disorder
1.021 (1.010–1.031)
<.001
Neurological condition
1.025 (1.015–1.035)
<.001
Heart disease
1.013 (1.002–1.024)
.020
Blood disease
1.016 (1.005–1.027)
.002
Secondary outcome§
Hospitalization
1.000 (1.000–1.000)
.77
Laboratory test
1.000 (0.998–1.003)
.78
Imaging
1.000 (0.999–1.002)
.16
Antibiotics use
1.000 (0.998–1.002)
.67
Return visit‡, ¶ 1.005 (0.999–1.011) .082
Subgroup analysis
Oseltamivir
1.011 (1.007–1.015)
<.001
Laninamivir
0.999 (0.996–1.003)
.81
Zanamivir
0.995 (0.991–0.999)
.039